Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.50 |
| ▸ | EIF4E | P06730 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505429 | 0.93 | DHODH (0.50) | CNR1EIF4ESRD5A2ALDH1A1TP53 | |
| SCHEMBL15392431 | 0.90 | EIF4E (0.45) | CNR1EIF4ESRD5A2DHODHDPP4 | |
| SCHEMBL4807852 | 0.85 | CNR1 (0.48) | CNR1EIF4ESRD5A2ALDH1A1TP53 | |
| SCHEMBL4515129 | 0.84 | HSD17B10 (0.58) | CNR1ALDH1A1TSHRSMN1; SMN2DPP4 | |
| SCHEMBL3880353 | 0.82 | CNR1 (0.46) | CNR1EIF4ESRD5A2ALDH1A1TP53 | |
| SCHEMBL4805584 | 0.81 | CNR1 (0.48) | CNR1EIF4E | |
| SCHEMBL4803179 | 0.80 | KDM4E (0.55) | ALDH1A1TP53SMN1; SMN2DHODH | |
| SCHEMBL15391230 | 0.79 | DHODH (0.49) | DHODH | |
| SCHEMBL4911902 | 0.77 | MALT1 (0.43) | CNR1DPP4DPP8 | |
| SCHEMBL15391905 | 0.76 | HSD17B10 (0.49) | CNR1ALDH1A1TSHRSMN1; SMN2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010492-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-01-07 | — | — | EP | disclosed |
| US-7345059-B2 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-03-18 | — | — | US | disclosed |
| WO-2007119001-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-10-25 | — | — | WO | disclosed |
| US-20060189664-A1 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189664-A1 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | CNR1, HDAC10, AKR1B10 | CNR1 1/4885EIF4E 1919/4885SRD5A2 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.